scholarly journals The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients

2009 ◽  
Vol 9 ◽  
pp. 1040-1045 ◽  
Author(s):  
Chad W. M. Ritenour ◽  
John T. Abbott ◽  
Michael Goodman ◽  
Naomi Alazraki ◽  
Fray F. Marshall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Bone Scan ◽  
Stage Migration ◽  
Gleason Grade ◽  
Newly Diagnosed ◽  
High Gleason Score ◽  
Bone Scans ◽  
The Relationship

Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive scans in a contemporary large series of newly diagnosed prostate cancer patients. Eight hundred consecutive cases of newly diagnosed prostate cancer over a 64-month period underwent a staging nuclear scan. All subjects had histologically confirmed cancer. The relationship between PSA, Gleason grade, and bone scan was examined by calculating series of crude, stratified, and adjusted odds ratios with corresponding 95% confidence intervals. Four percent (32/800) of all bone scans were positive. This proportion was significantly lower in patients with Gleason score ≤7 (1.9%) vs. Gleason score ≥8 (18.8%,p< 0.001). Among patients with Gleason score ≤7, the rate of positive bones scans was 70-fold higher when the PSA was >30 ng/ml compared to ≤30 ng/ml (p< 0.001). For Gleason score ≥8, the rate was significantly higher (27.9 vs. 0%) when PSA was >10 ng/ml compared to ≤10 ng/ml (p= 0.002). The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients. The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores ≤7, we recommend a bone scan if the PSA is >30 ng/ml. However, for patients with a high Gleason score (8–10), we recommend a bone scan if the PSA is >10 ng/ml.

scholarly journals Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis NIH category IV and the Gleason score in patients with prostate cancer?

2019 ◽  
Vol 14 (11) ◽  
Author(s):  
Erdogan Aglamis ◽  
Cavit Ceylan ◽  
Mustafa Akin
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Needle Biopsy ◽  
Newly Diagnosed ◽  
Prostate Needle Biopsy ◽  
Retrospective Design ◽  
Biopsy Specimens ◽  
Grade 3 ◽  
Prostatic Inflammation

Introduction: We evaluated the correlation between the International Society of Urological Pathology (ISUP) grades and the aggressiveness grades of prostate inflammation in newly diagnosed prostate cancer patients with chronic asymptomatic prostatitis National Institiutes of Health (NIH) category IV (CAPNIHIV). Methods: The study comprised 357 consecutive patients with prostate cancer in whom a cancer diagnosis had been made via a prostate needle biopsy. Histological sections of the prostate biopsy specimens of the patients were reviewed and scored. Prostatic inflammation was scored using the aggressiveness grade of inflammation. The associations between the ISUP grades and the aggressiveness grades of inflammation were analyzed using logistic regression. The limitations of the study were its retrospective design and the limited number of cases. Results: In 110 (31%) patients, CAPNIHIV was detected: 56 (51%) patients had a grade 0 aggressiveness score, 34 (31%) patients had a grade 1 aggressiveness score, and 20 (18%) patients had a grade 2 aggressiveness score. The patients who had prostatic inflammation had a 1.65 times (95% confidence interval [CI] 1.05–2.61) greater likelihood of a high ISUP grade (grade ≥3) compared with the patients who did not have prostatic inflammation. The association between the ISUP grade and the aggressiveness grade of inflammation was more pronounced for a grade 2 aggressiveness score (n= 20; odds ratio 2.97; 95% CI 1.14–7.71). Conclusions: In prostate cancer patients with CAPNIHIV, there was a positive correlation between the inflammation aggressiveness grade and the ISUP grade. The aggressiveness of intraprostatic inflammation may be an important morphological factor affecting the Gleason score.

S81 THE NARROWING RANGE OF BONE SCAN IN NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: A RETROSPECTIVE COMPERATIVE STUDY

2012 ◽  
Vol 11 (4) ◽  
pp. 153
Author(s):  
B.C. Ozgur ◽  
S. Gültekin ◽  
M. Ekici ◽  
D. Yilmazer ◽  
M. Alper
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Bone Scan ◽  
Newly Diagnosed

Primary hormonal therapy for patients with localized or locally advanced prostate cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14630-14630
Author(s):  
Z. Shklar ◽  
R. Rubinov ◽  
M. Steiner ◽  
A. Rabkin ◽  
M. Leviov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Hormonal Therapy ◽  
Locally Advanced ◽  
High Gleason Score ◽  
Clinical Difference ◽  
Median Serum ◽  
Radical Therapy ◽  
Psa Recurrence

14630 Background: During 1998–2000, 68 patients with localized or locally advanced prostate carcinoma who were not suitable for radical therapy received primary hormonal therapy as the only treatment modality. The group consisted 15.8% of all prostate cancer patients referred to our center during the three years period. Methods: Their median age was 76.7 years (65–89). 42.4% had T1c disease, 30.3% T2a, 15.2% stage T2b and 12.1% T3. 78.4% had Gleason score 4–6, 10.8% Gleason 7 and 10.8% Gleason 8–10 prostate cancer. Median serum PSA level before starting therapy was 15.8 ng/ml (3.4–289). 76% received LHRH agonists monotherapy while 24% had complete androgen blockade. Patients were followed using repeated serum PSA level during 39–95 months (median 79.5). Results: 32/68 patients (47%) experienced PSA recurrence during the study period. Median time to PSA failure was 38.9 months (13–77). No clinical difference was observed between recurrent and non recurrent patients as regarding stage of disease or type of hormonal therapy. In relapsing patients high Gleason score (7–10) was more common (32.3% vs 11.6%) and median initial serum PSA value was higher (22.4 vs 14.5 ng/ml) than in the non recurrent group. During the study period, only 4/68 patients (5.9%) developed clinical disease, 10/68 patients (14.7%) died of unrelated causes and no patient died of prostate cancer. Conclusions: We conclude that primary hormonal therapy is a safe option for prostate cancer patients not suitable for more radical procedures. As expected, high Gleason score and higher initial serum PSA value are predictive for earlier relapse. No significant financial relationships to disclose.

scholarly journals A Hierarchical Machine Learning Model to Discover Gleason Grade Group-specific Biomarkers in Prostate Cancer

2019 ◽  
Author(s):  
Osama Hamzeh ◽  
Abedalrhman Alkhateeb ◽  
Julia Zheng ◽  
Srinath Kandalam ◽  
Crystal Lueng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Machine Learning ◽  
Cancer Patients ◽  
Gleason Score ◽  
Cancer Progression ◽  
Class Imbalance ◽  
Gleason Grade ◽  
Gene Expressions ◽  
Grade Group ◽  
Potential Biomarkers

1) Background: One of the deadliest cancers that affect men worldwide and North American men is prostate cancer. This disease motivates parts of the cells in the prostate to lose control of their growth and division. 2) Methods: We are proposing a machine learning method used to analyze gene expressions of prostate tumors with different Gleason scores, and to identify potential genetic biomarkers for each group. A publicly-available RNA-Seq dataset of a cohort of 104 prostate cancer patients have been retrieved from the National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO) repository. We categorize patients by their Gleason scores into different groups to create a hierarchy of disease progression. A hierarchical model with standard classifiers in different Gleason groups (hereinafter called nodes) to identify and predict nodes based on their mRNA or gene expressions. At each node, patient samples are analyzed via class imbalance and hybrid feature selection techniques to build the prediction model. The outcome of each node is a set of genes that can separate the Gleason group from the remaining groups. To validate the proposed method, the set of identified genes are used to classify a second dataset of 499 prostate cancer patients that have been collected from cBioportal.. 3) Results: Two genes have been found to be potential biomarkers of specific Gleason groups; PIAS3 has been identifed for Gleason score 4+3=7, while UBE2 could be a poteintial biomarker for Gleason score 6. Other proposed genes that were not found in the literature might be potential biomarkers. 4) Conclusion: The latest literature supports that the genes predicted by the proposed method are strongly correlated with prostate cancer progression and tumour development processes. Furthermore, pathway analysis shows that both PIAS3 and UBE2 share the same protein interaction pathway, the JAK/STAT signaling process.

Sign in / Sign up

Export Citation Format

Share Document